Advertisement
Loading...

Oculis Holding AG

OCSNASDAQ
Healthcare
Biotechnology
$30.41
$-2.24(-6.86%)
U.S. Market opens in 6h 4m

Oculis Holding AG Fundamental Analysis

Oculis Holding AG (OCS) shows weak financial fundamentals with a PE ratio of -13.50, profit margin of -195.99%, and ROE of -62.46%. The company generates $0.0B in annual revenue with weak year-over-year growth of -1.00%.

Key Strengths

Cash Position12.53%
PEG Ratio-2.57
Current Ratio5.96

Areas of Concern

ROE-62.46%
Operating Margin-162.54%
We analyze OCS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -14833.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-14833.5/100

We analyze OCS's fundamental strength across five key dimensions:

Efficiency Score

Weak

OCS struggles to generate sufficient returns from assets.

ROA > 10%
-41.81%

Valuation Score

Excellent

OCS trades at attractive valuation levels.

PE < 25
-13.50
PEG Ratio < 2
-2.57

Growth Score

Moderate

OCS shows steady but slowing expansion.

Revenue Growth > 5%
-1.00%
EPS Growth > 10%
14.62%

Financial Health Score

Excellent

OCS maintains a strong and stable balance sheet.

Debt/Equity < 1
0.01
Current Ratio > 1
5.96

Profitability Score

Weak

OCS struggles to sustain strong margins.

ROE > 15%
-6245.78%
Net Margin ≥ 15%
-195.99%
Positive Free Cash Flow
No

Key Financial Metrics

Is OCS Expensive or Cheap?

P/E Ratio

OCS trades at -13.50 times earnings. This suggests potential undervaluation.

-13.50

PEG Ratio

When adjusting for growth, OCS's PEG of -2.57 indicates potential undervaluation.

-2.57

Price to Book

The market values Oculis Holding AG at 6.80 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

6.80

EV/EBITDA

Enterprise value stands at -15.12 times EBITDA. This is generally considered low.

-15.12

How Well Does OCS Make Money?

Net Profit Margin

For every $100 in sales, Oculis Holding AG keeps $-195.99 as profit after all expenses.

-195.99%

Operating Margin

Core operations generate -162.54 in profit for every $100 in revenue, before interest and taxes.

-162.54%

ROE

Management delivers $-62.46 in profit for every $100 of shareholder equity.

-62.46%

ROA

Oculis Holding AG generates $-41.81 in profit for every $100 in assets, demonstrating efficient asset deployment.

-41.81%

Following the Money - Real Cash Generation

Operating Cash Flow

Oculis Holding AG generates limited operating cash flow of $-66.99M, signaling weaker underlying cash strength.

$-66.99M

Free Cash Flow

Oculis Holding AG generates weak or negative free cash flow of $-68.41M, restricting financial flexibility.

$-68.41M

FCF Per Share

Each share generates $-1.20 in free cash annually.

$-1.20

FCF Yield

OCS converts -4.90% of its market value into free cash.

-4.90%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-13.50

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-2.57

vs 25 benchmark

P/B Ratio

Price to book value ratio

6.80

vs 25 benchmark

P/S Ratio

Price to sales ratio

2702.65

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.01

vs 25 benchmark

Current Ratio

Current assets to current liabilities

5.96

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.62

vs 25 benchmark

ROA

Return on assets percentage

-0.42

vs 25 benchmark

ROCE

Return on capital employed

-0.41

vs 25 benchmark

How OCS Stacks Against Its Sector Peers

MetricOCS ValueSector AveragePerformance
P/E Ratio-13.5029.24 Better (Cheaper)
ROE-62.46%713.00% Weak
Net Margin-19598.87%-42604.00% (disorted) Weak
Debt/Equity0.010.46 Strong (Low Leverage)
Current Ratio5.964.36 Strong Liquidity
ROA-41.81%-16668.00% (disorted) Weak

OCS outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Oculis Holding AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-297.26%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-223.38%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ